ACELRX PHARMACEUTICALS INC (ACRX) Fundamental Analysis & Valuation

NASDAQ:ACRX • US00444T2096

Current stock price

0.86 USD
+0.06 (+7.5%)
At close:
0.8719 USD
+0.01 (+1.38%)
After Hours:

This ACRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ACRX Profitability Analysis

1.1 Basic Checks

  • In the past year ACRX has reported negative net income.
  • In the past year ACRX has reported a negative cash flow from operations.
ACRX Yearly Net Income VS EBIT VS OCF VS FCFACRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M

1.2 Ratios

  • With a Return On Assets value of -113.65%, ACRX is not doing good in the industry: 84.31% of the companies in the same industry are doing better.
  • ACRX has a Return On Equity of -144.70%. This is in the lower half of the industry: ACRX underperforms 68.63% of its industry peers.
Industry RankSector Rank
ROA -113.65%
ROE -144.7%
ROIC N/A
ROA(3y)-5.62%
ROA(5y)-22.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACRX Yearly ROA, ROE, ROICACRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 500 -500 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ACRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACRX Yearly Profit, Operating, Gross MarginsACRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 1K -1K 2K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ACRX Health Analysis

2.1 Basic Checks

  • ACRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ACRX has been increased compared to 1 year ago.
  • Compared to 1 year ago, ACRX has an improved debt to assets ratio.
ACRX Yearly Shares OutstandingACRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M
ACRX Yearly Total Debt VS Total AssetsACRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • ACRX has an Altman-Z score of -26.92. This is a bad value and indicates that ACRX is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -26.92, ACRX is doing worse than 88.73% of the companies in the same industry.
  • ACRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.92
ROIC/WACCN/A
WACC9.57%
ACRX Yearly LT Debt VS Equity VS FCFACRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 20M -20M -40M

2.3 Liquidity

  • ACRX has a Current Ratio of 4.00. This indicates that ACRX is financially healthy and has no problem in meeting its short term obligations.
  • ACRX has a Current ratio of 4.00. This is comparable to the rest of the industry: ACRX outperforms 55.39% of its industry peers.
  • ACRX has a Quick Ratio of 4.00. This indicates that ACRX is financially healthy and has no problem in meeting its short term obligations.
  • ACRX's Quick ratio of 4.00 is in line compared to the rest of the industry. ACRX outperforms 57.84% of its industry peers.
Industry RankSector Rank
Current Ratio 4
Quick Ratio 4
ACRX Yearly Current Assets VS Current LiabilitesACRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ACRX Growth Analysis

3.1 Past

  • ACRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.88%, which is quite impressive.
  • ACRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -37.23%.
  • The Revenue for ACRX have been decreasing by -26.04% on average. This is quite bad
EPS 1Y (TTM)50.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.49%
Revenue 1Y (TTM)-37.23%
Revenue growth 3Y-8.23%
Revenue growth 5Y-26.04%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ACRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.09% on average per year.
  • The Revenue is expected to grow by 36.49% on average over the next years. This is a very strong growth
EPS Next Y72.27%
EPS Next 2Y34.78%
EPS Next 3Y22.12%
EPS Next 5Y15.09%
Revenue Next Year-91.49%
Revenue Next 2Y-52.31%
Revenue Next 3Y-25.27%
Revenue Next 5Y36.49%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ACRX Yearly Revenue VS EstimatesACRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M
ACRX Yearly EPS VS EstimatesACRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 5 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

1

4. ACRX Valuation Analysis

4.1 Price/Earnings Ratio

  • ACRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ACRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRX Price Earnings VS Forward Price EarningsACRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRX Per share dataACRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ACRX's earnings are expected to grow with 22.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.78%
EPS Next 3Y22.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ACRX Dividend Analysis

5.1 Amount

  • No dividends for ACRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ACRX Fundamentals: All Metrics, Ratios and Statistics

ACELRX PHARMACEUTICALS INC

NASDAQ:ACRX (1/9/2024, 8:00:00 PM)

After market: 0.8719 +0.01 (+1.38%)

0.86

+0.06 (+7.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-08
Earnings (Next)03-28
Inst Owners22.97%
Inst Owner Change56.73%
Ins Owners3.13%
Ins Owner Change0%
Market Cap14.58M
Revenue(TTM)620.00K
Net Income(TTM)-26.48M
Analysts82.5
Price Target4.72 (448.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49%
Min EPS beat(2)26.01%
Max EPS beat(2)71.99%
EPS beat(4)3
Avg EPS beat(4)13.22%
Min EPS beat(4)-92.23%
Max EPS beat(4)71.99%
EPS beat(8)7
Avg EPS beat(8)14.45%
EPS beat(12)10
Avg EPS beat(12)10.52%
EPS beat(16)12
Avg EPS beat(16)9.08%
Revenue beat(2)1
Avg Revenue beat(2)108.13%
Min Revenue beat(2)-10.53%
Max Revenue beat(2)226.8%
Revenue beat(4)1
Avg Revenue beat(4)5.43%
Min Revenue beat(4)-100%
Max Revenue beat(4)226.8%
Revenue beat(8)1
Avg Revenue beat(8)-47.29%
Revenue beat(12)1
Avg Revenue beat(12)-47.44%
Revenue beat(16)2
Avg Revenue beat(16)-44.57%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26%
EPS NY rev (1m)0%
EPS NY rev (3m)20.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.51
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 1.53
EV/EBITDA N/A
EPS(TTM)-2.23
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS0.04
BVpS1.08
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -113.65%
ROE -144.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-5.62%
ROA(5y)-22.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.54%
Cap/Sales 22.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4
Quick Ratio 4
Altman-Z -26.92
F-Score5
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)71.75%
Cap/Depr(5y)112.88%
Cap/Sales(3y)39.85%
Cap/Sales(5y)61.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.49%
EPS Next Y72.27%
EPS Next 2Y34.78%
EPS Next 3Y22.12%
EPS Next 5Y15.09%
Revenue 1Y (TTM)-37.23%
Revenue growth 3Y-8.23%
Revenue growth 5Y-26.04%
Sales Q2Q%N/A
Revenue Next Year-91.49%
Revenue Next 2Y-52.31%
Revenue Next 3Y-25.27%
Revenue Next 5Y36.49%
EBIT growth 1Y11.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.11%
OCF growth 3YN/A
OCF growth 5YN/A

ACELRX PHARMACEUTICALS INC / ACRX Fundamental Analysis FAQ

What is the fundamental rating for ACRX stock?

ChartMill assigns a fundamental rating of 3 / 10 to ACRX.


Can you provide the valuation status for ACELRX PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to ACELRX PHARMACEUTICALS INC (ACRX). This can be considered as Overvalued.


How profitable is ACELRX PHARMACEUTICALS INC (ACRX) stock?

ACELRX PHARMACEUTICALS INC (ACRX) has a profitability rating of 0 / 10.


What is the financial health of ACELRX PHARMACEUTICALS INC (ACRX) stock?

The financial health rating of ACELRX PHARMACEUTICALS INC (ACRX) is 6 / 10.